🎉 M&A multiples are live!
Check it out!

Ascentage Pharma Group Valuation Multiples

Discover revenue and EBITDA valuation multiples for Ascentage Pharma Group and similar public comparables like Vivoryon Therapeutics, Pharming, and Galapagos.

Ascentage Pharma Group Overview

About Ascentage Pharma Group

Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The company's geographical segments include the United States and Mainland China.


Founded

2009

HQ

Hong Kong
Employees

583

Financials

LTM Revenue $126M

LTM EBITDA -$67.3M

EV

$1.8B

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Ascentage Pharma Group Financials

Ascentage Pharma Group has a last 12-month revenue of $126M and a last 12-month EBITDA of -$67.3M.

In the most recent fiscal year, Ascentage Pharma Group achieved revenue of $28.5M and an EBITDA of -$95.6M.

Ascentage Pharma Group expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Ascentage Pharma Group valuation multiples based on analyst estimates

Ascentage Pharma Group P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $27.0M $28.5M XXX XXX XXX
Gross Profit $3.2M $24.1M XXX XXX XXX
Gross Margin 12% 85% XXX XXX XXX
EBITDA -$99.2M -$95.6M XXX XXX XXX
EBITDA Margin -368% -335% XXX XXX XXX
Net Profit -$101M -$114M XXX XXX XXX
Net Margin -373% -398% XXX XXX XXX
Net Debt n/a $38.6M XXX XXX XXX

Financial data powered by Morningstar, Inc.

Ascentage Pharma Group Stock Performance

As of April 15, 2025, Ascentage Pharma Group's stock price is HKD 38 (or $5).

Ascentage Pharma Group has current market cap of HKD 13.4B (or $1.7B), and EV of HKD 13.8B (or $1.8B).

See Ascentage Pharma Group trading valuation data

Ascentage Pharma Group Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$1.8B $1.7B XXX XXX XXX XXX $-0.24

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Ascentage Pharma Group Valuation Multiples

As of April 15, 2025, Ascentage Pharma Group has market cap of $1.7B and EV of $1.8B.

Ascentage Pharma Group's trades at 15.1x LTM EV/Revenue multiple, and -28.3x LTM EBITDA.

Analysts estimate Ascentage Pharma Group's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Ascentage Pharma Group and 10K+ public comps

Ascentage Pharma Group Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $1.8B XXX XXX XXX
EV/Revenue 62.4x XXX XXX XXX
EV/EBITDA -18.6x XXX XXX XXX
P/E -14.5x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -17.7x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Ascentage Pharma Group Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Ascentage Pharma Group Valuation Multiples

Ascentage Pharma Group's NTM/LTM revenue growth is 25%

Ascentage Pharma Group's revenue per employee for the last fiscal year averaged $49K, while opex per employee averaged $0.2M for the same period.

Over next 12 months, Ascentage Pharma Group's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Ascentage Pharma Group's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Ascentage Pharma Group and other 10K+ public comps

Ascentage Pharma Group Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 6% XXX XXX XXX XXX
EBITDA Margin -335% XXX XXX XXX XXX
EBITDA Growth -4% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -310% XXX XXX XXX XXX
Revenue per Employee $49K XXX XXX XXX XXX
Opex per Employee $0.2M XXX XXX XXX XXX
S&M Expenses to Revenue 88% XXX XXX XXX XXX
G&A Expenses to Revenue 82% XXX XXX XXX XXX
R&D Expenses to Revenue 318% XXX XXX XXX XXX
Opex to Revenue 479% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Ascentage Pharma Group Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Small Molecules comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Ascentage Pharma Group M&A and Investment Activity

Ascentage Pharma Group acquired  XXX companies to date.

Last acquisition by Ascentage Pharma Group was  XXXXXXXX, XXXXX XXXXX XXXXXX . Ascentage Pharma Group acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Ascentage Pharma Group

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Ascentage Pharma Group

When was Ascentage Pharma Group founded? Ascentage Pharma Group was founded in 2009.
Where is Ascentage Pharma Group headquartered? Ascentage Pharma Group is headquartered in Hong Kong.
How many employees does Ascentage Pharma Group have? As of today, Ascentage Pharma Group has 583 employees.
Who is the CEO of Ascentage Pharma Group? Ascentage Pharma Group's CEO is Dr. Dajun Yang, M.D.,PhD.
Is Ascentage Pharma Group publicy listed? Yes, Ascentage Pharma Group is a public company listed on HKG.
What is the stock symbol of Ascentage Pharma Group? Ascentage Pharma Group trades under 06855 ticker.
When did Ascentage Pharma Group go public? Ascentage Pharma Group went public in 2019.
Who are competitors of Ascentage Pharma Group? Similar companies to Ascentage Pharma Group include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Ascentage Pharma Group? Ascentage Pharma Group's current market cap is $1.7B
What is the current revenue of Ascentage Pharma Group? Ascentage Pharma Group's last 12-month revenue is $126M.
What is the current EBITDA of Ascentage Pharma Group? Ascentage Pharma Group's last 12-month EBITDA is -$67.3M.
What is the current EV/Revenue multiple of Ascentage Pharma Group? Current revenue multiple of Ascentage Pharma Group is 15.1x.
What is the current EV/EBITDA multiple of Ascentage Pharma Group? Current EBITDA multiple of Ascentage Pharma Group is -28.3x.
What is the current revenue growth of Ascentage Pharma Group? Ascentage Pharma Group revenue growth between 2023 and 2024 was 6%.
Is Ascentage Pharma Group profitable? Yes, Ascentage Pharma Group is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.